Warning Letter — FairyGene, Inc.
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to FairyGene, Inc. following a compliance review. The notice indicates significant deviations from regulatory standards identified by the agency.
This action directly affects FairyGene, Inc. and its internal departments responsible for regulatory compliance, manufacturing quality, and facility management.
The issuance of a Warning Letter by CDER suggests that the facility's current manufacturing or quality control processes may not meet statutory requirements. This represents a formal escalation of enforcement that could lead to seizure of products, injunctions, or restrictions on federal contract awards if the cited deficiencies are not remediated.
Regulatory and QA teams should conduct a thorough review of site-specific manufacturing documentation and ensure all facility registrations are current. Facilities receiving such letters must prepare a formal response addressing the specific compliance deficiencies noted by CDER to mitigate further enforcement actions.
FDA Warning Letter issued to: FairyGene, Inc.. 07/31/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fairygene-inc-726976-07312026
Open in openFDA / FDA.gov